1. Home
  2. NUWE vs RDHL Comparison

NUWE vs RDHL Comparison

Compare NUWE & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuwellis Inc.

NUWE

Nuwellis Inc.

N/A

Current Price

$3.77

Market Cap

3.2M

Sector

Health Care

ML Signal

N/A

Logo Redhill Biopharma Ltd.

RDHL

Redhill Biopharma Ltd.

N/A

Current Price

$0.32

Market Cap

3.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NUWE
RDHL
Founded
1999
2009
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2M
3.7M
IPO Year
2012
2012

Fundamental Metrics

Financial Performance
Metric
NUWE
RDHL
Price
$3.77
$0.32
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 1.4M
76.6K
Earning Date
11-12-2026
09-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $8,270,000.00
N/A
Revenue This Year
$19.32
$17,592.31
Revenue Next Year
$12.01
$25.89
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.28
$0.33
52 Week High
$222.30
$1.60

Technical Indicators

Market Signals
Indicator
NUWE
RDHL
Relative Strength Index (RSI) 40.20 28.25
Support Level $0.28 N/A
Resistance Level $5.74 $0.47
Average True Range (ATR) 0.51 0.04
MACD 0.02 -0.00
Stochastic Oscillator 0.86 3.10

Price Performance

Historical Comparison
NUWE
RDHL

About NUWE Nuwellis Inc.

Nuwellis Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.

About RDHL Redhill Biopharma Ltd.

RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.

Share on Social Networks: